Gastroparesis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Gastroparesis Market Outlook

Thelansis’s “Gastroparesis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastroparesis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastroparesis Overview

Gastroparesis (GP) is a syndrome where gastric emptying is delayed without any mechanical obstruction in the gastric outlet. Common symptoms include postprandial fullness (early satiety), nausea, vomiting, and abdominal pain. Nausea is observed in over 90% of patients, while vomiting affects 68% to 84%. Around half of the patients experience feelings of fullness or early satiety even after consuming a small amount of food. Vomiting typically consists of poorly digested food from 1 to 12 hours ago, often accompanied by acid reflux, nausea, abdominal bloating, abdominal pain, changes in blood sugar levels, appetite loss, weight loss, and malnutrition. Bloating and abdominal pain are primarily attributed to sensory changes, while nausea, vomiting, early satiety, and postprandial fullness stem from issues with smooth muscle function and neural denervation, resulting in delayed gastric emptying. It's important to note that psychological disorders do not cause gastric retention in these patients, although psychological distress can exacerbate a patient's perception of symptom severity.

• The prevalence of cases of Gastroparesis in the USA is 268 to 339 cases per 100,000 population. It was more than twice as common in females than males, with patients aged 58 to 64 years having the highest prevalence and those aged 18 to 27 years having the lowest.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: